Sir Richard Sykes, DSc, FRS, FMedSci, HonFREng
(Executive Chairman of the Board)
Sir Richard Sykes is currently Chairman of Imperial College Healthcare NHS Trust, Chairman of the Royal Institution of Great Britain, Chairman of the UK Stem Cell Foundation, Chairman of Omnicyte, NetScientific and the investment board of Deepridge Capital. He was appointed Chancellor of Brunel University in 2013. Prior to that, he was Senior Independent Director and non executive Chairman of ENRC from 2007 to June 2011, Chairman of NHS London from December 2008 to July 2010, Rector of Imperial College London from 2000 to 2008. He was a non executive director of Rio Tinto plc from 1997 to 2007, and senior independent director from 2004 to 2007. He has over 30 years’ experience within the biotechnology and pharmaceutical industries field, serving as Chief Executive and Chairman of GlaxoWellcome from 1995 to 2000 and then as Chairman of GlaxoSmithkline until 2002. Internationally he is Chairman of the International Advisory Board, A*Star Biomedical Research Council, Singapore and a Board member of EDBI. He was awarded Honorary Citizenship of Singapore in 2004 for his contribution to the development of the country’s biomedical sciences industry. Sir Richard holds a number of degrees and awards from Institutions both in the UK and overseas. He is a Fellow of the Royal Society and Academy of Medical Sciences, and an Honorary Fellow of the Royal Academy of Engineering, Royal Society of Chemistry, Royal Pharmaceutical Society, Royal College of Pathologists and the Royal College of Physicians. He is also President of the R and D Society, a position he has held since 2002. He is a Fellow of Imperial College London and the Imperial College School of Medicine, King’s College London and Honorary Fellow of the Universities of Wales and Central Lancashire. Sir Richard received a Knighthood in the 1994 New Year’s Honours list for services to the pharmaceutical industry.
Ian Postlethwaite, is Chief Financial Officer and Board of Directors member of the NetScientific Plc, and Deputy Chairman of Shoreham Port. He joined NetScientific in June 2016. NetScientific is a transatlantic healthcare IP commercialisation Group focused on improving the health and wellbeing of people with chronic diseases. He was previously Finance Director and a member of the Board of Directors for 14 years of Allergy Therapeutics Plc. He joined Allergy in April 2002, whilst it was private company, initially performing a financial turnaround and then listing it two years later in 2004 on the AIM of the London Stock Exchange. Revenue increased from £12m to £49m over his tenure and he raised £107m through equity issues and €40m through debt finance to fund over 15 clinical studies, including 3 phase III studies. Prior to this he worked for Ellerman Investments (1997 – 2002), a UK private equity house, undertaking the roles of Chief Executive Officer with AFS, which was one of the largest independent finance houses in the UK, raising over £400m in debt finance, and Finance Director of a number of their successful start-up technology companies. Previously he held senior finance positions with Ericsson and Philips Electronics.
He is a Fellow of the Chartered Association of Certified Accountants and has a BSc (Hons) in Geological Sciences from Aston University.
De Lyle W. Bloomquist
De Lyle W. Bloomquist retired in March 2015 as the President, Global Chemicals Business for Tata Chemicals Ltd. as well as the President, CEO and Director of Tata Chemicals North America Inc. (the former General Chemical), which he was instrumental in selling to Tata Chemicals for over $1 billion in 2008. During his over 28 year career, he has held positions in finance, manufacturing, sales & marketing, logistics and general management. He has experience in taking companies public and private, raising financing in the public markets as well as with banks and private investors. Mr. Bloomquist serves on the Boards of Directors for Rayonier Advanced Materials (NYSE: RYAM), Huber Engineered Materials, PDS Biotechnology Corporation, Crystal Peak Minerals and Costa Farms, and has served in past on the Boards of ANSAC and Oglebay Norton. He currently serves on the compensation and audit committees for RYAM, the technical and audit committees for Crystal Peak Minerals, and the compensation committee for Costa Farms. He also serves on the Board of Business Advisors for the Tepper School of Business at Carnegie Mellon University.
Frank K. Bedu-Addo, Ph.D.
President and CEO
Frank is a veteran biotech executive with experience successfully starting and growing biotechnology organizations. He has been responsible for the development and implementation of both operational and drug development strategies, supervising and managing both large organizations as well as emerging biotechnology companies. Dr. Bedu-Addo was a founding and senior executive at KBI BioPharma, Inc. As Vice President of Drug Development he oversaw all business and drug development operations. Before being hired by KBI, he successfully started and managed Cardinal Health’s east coast biotechnology drug development operations. Prior to Cardinal Health, Dr. Bedu-Addo was also an Associate Director at Akzo-Nobel, Senior Scientist at Elan (The Liposome Co.), and Principal Scientist at Schering-Plough. In these positions he participated in the development of numerous drugs, including antiviral and anticancer drugs. He has also served on biotech boards. Dr. Bedu-Addo obtained his M.S. in chemical engineering and Ph.D. in pharmaceutics from the University of Pittsburgh.
Gregory G. Freitag, J.D., CPA
Gregory G. Freitag, J.D., CPA, is AxoGen, Inc.’s (NASDAQ: AXGN) General Counsel, SVP of Business Development and a member of its Board of Directors and was its Chief Financial Officer. AxoGen, Inc. is a leading regenerative medicine company dedicated to peripheral nerve repair. Mr. Freitag was Chief Executive Officer, Chief Financial Officer and a board member from June 2010 through September 2011 of LecTec Corporation, an intellectual property licensing and holding company that merged with AxoGen in September 2011. Mr. Freitag is a principal of FreiMc, LLC, a health care and life science consulting and advisory firm he founded that provides strategic guidance and business development services. Prior to founding FreiMc, Mr. Freitag was a Director of Business Development at Pfizer Health Solutions, a former subsidiary of Pfizer, Inc. and worked for Guidant Corporation in their business development group. Prior to Guidant Corporation, Mr. Freitag was the Chief Executive Officer of HTS Biosystems, a biotechnology tools start-up company and was the Chief Operating Officer, Chief Financial Officer and General Counsel of Quantech, Ltd. Prior to Quantech, Mr. Freitag practiced corporate law in Minneapolis, Minnesota. Mr. Freitag is also a director of the Foundation Board of HealthEast Care System, a health care system in Minnesota.